ArticleScientific reports2026
Identification of an age-related monocyte-derived macrophages characteristic genes-based signature for high-grade diffuse glioma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Monocyte-derived macrophages (MDMs) have been associated with increased infiltration proportion and shorter overall survival (OS) in diffuse gliomas (DGs), particularly contributing to poor prognosis in elderly patients. However, the criteria for predicting the suitability and efficacy of MDM-targeted therapy in cancer treatment remain unclear. This study utilized TCGA and CGGA high-grade diffuse glioma cohorts (IDH-wildtype glioblastoma or IDH-mutant astrocytoma, CNS WHO grade 4) with complete mRNA expression profiles and clinical information. The MDM intersect gene set was obtained through differential gene analysis and single cell RNA-sequencing analysis, followed by the application of least absolute shrinkage and selection operator (LASSO) algorithm to identify core genes for risk score (RS) modeling. Using the TCGA dataset as a training set and CGGA dataset as a validation set, we verified that RS, including G0S2, PLAUR, and SPAG4 gene expressions, is a reliable indicator of poor prognosis in high-grade DGs patients. Our findings demonstrate that RS can serve as an infiltration index for MDMs enabling accurate prediction of high-grade DGs patient prognosis. Furthermore, we found that in glioblastoma (GBM), a more malignant subtype of diffuse glioma, monitoring this index and targeting MDMs is crucial for improving overall survival, especially in older female patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.